Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anticoagulation Therapeutic Ranges and Clinical Outcomes in Patients with a Mechanical Heart Valve Treated with Vitamin K Antagonists-a Nationwide Linked-data Dutch Study.

Thrombosis and haemostasis·2026
Same author

Changes in quality of vitamin K antagonist treatment and clinical outcomes during Ramadan: a Dutch population-based cohort study.

Research and practice in thrombosis and haemostasis·2025
Same author

Polymorphisms in the adrenergic neurotransmission pathway impact antidepressant response in depressed patients.

Neuroscience applied·2025
Same author

Optimization of vitamin K antagonist treatment: Near patient monitoring versus standard of care a parallel group clinical trial in older patients with atrial fibrillation.

European journal of clinical pharmacology·2025
Same author

Low-cost generation of clinical-grade, layperson-friendly pharmacogenetic passports using oligonucleotide arrays.

American journal of human genetics·2025
Same author

Overdoses and deaths related to the use of ketamine and its analogues: a systematic review.

The American journal of drug and alcohol abuse·2022

Related Experiment Video

Updated: Jun 26, 2026

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
14:39

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Published on: April 22, 2022

Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.

Maarten Beinema1, Jacobus R B J Brouwers, Tom Schalekamp

  • 1Thrombosis Centre, Deventer Hospital, PO box 5001, 7400GC Deventer, The Netherlands. BeinemaM@dz.nl

Thrombosis and Haemostasis
|January 10, 2009
PubMed
Summary

Genetic variations in VKORC1 and CYP2C9 significantly impact warfarin dosing and bleeding risk. Phenprocoumon may be preferable for long-term anticoagulation without genetic testing.

Related Experiment Videos

Last Updated: Jun 26, 2026

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults
14:39

Semi-Targeted Ultra-High-Performance Chromatography Coupled to Mass Spectrometry Analysis of Phenolic Metabolites in Plasma of Elderly Adults

Published on: April 22, 2022

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Clinical Pharmacology

Background:

  • Coumarin oral anticoagulants, like warfarin, are crucial for preventing thromboembolic events.
  • VKORC1 and CYP2C9 genetic variations significantly influence patient response to these drugs.
  • Inter-individual differences in drug dosage and bleeding risk are often linked to these genotypes.

Purpose of the Study:

  • To investigate the impact of VKORC1 and CYP2C9 genotypes on coumarin anticoagulant therapy.
  • To compare the effects of different coumarin anticoagulants in relation to these genetic polymorphisms.
  • To determine the optimal choice of anticoagulant in the absence of pharmacogenetic testing.

Main Methods:

  • Review of existing literature on VKORC1 and CYP2C9 polymorphisms and their effect on coumarin anticoagulants.
  • Analysis of pharmacokinetic and pharmacodynamic data related to warfarin, acenocoumarol, and phenprocoumon.
  • Comparison of therapeutic outcomes, including International Normalized Ratio (INR) stability and monitoring frequency.

Main Results:

  • VKORC1 and CYP2C9 genotypes are major determinants of inter-individual variability in coumarin anticoagulant dosage.
  • Individuals with both variant genotypes face an increased risk of major bleeding, particularly during initial therapy.
  • Phenprocoumon exhibits the least pronounced effects of CYP2C9 polymorphisms, leading to more stable INR values and fewer monitoring visits in the long term.

Conclusions:

  • Phenprocoumon appears preferable for long-term anticoagulation when pharmacogenetic testing is unavailable.
  • Pharmacogenetic testing prior to initiating coumarin anticoagulants can enhance safety, especially in elderly patients on multiple medications.
  • Understanding genetic influences is key to optimizing anticoagulant therapy and minimizing adverse events.